Open AccessKinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies
Author(s) -
Rand Shahin,
Salah Aljamal
Publication year - 2022
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2021-0116
Subject(s) - vinca , kinesin , mitosis , antimitotic agent , cancer , microtubule , cancer cell , drug discovery , cell cycle , cancer treatment , pharmacology , cancer research , chemistry , computational biology , medicine , biology , bioinformatics , microbiology and biotechnology , tubulin
Bringing to a halt the cell cycle in mitosis and interfering with its normal progression is one of the most successful anti-cancer strategies used nowadays. Classically, several kinds of anti-cancer drugs like taxanes and vinca alkaloids directly inhibit microtubules during cell division. These drugs exhibit serious side effects, most importantly, severe peripheral neuropathies. Alternatively, KSP inhibitors are grasping a lot of research attention as less toxic mitotic inhibitors. In this review, we track the medicinal chemistry developmental stages of KSP inhibitors. Moreover, we address the challenges that are faced during the development of KSP inhibitor therapy for cancer and future insights for the latest advances in research that are directed to find active KSP inhibitor drugs.